Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
HOWL

HOWL - Werewolf Therapeutics, Inc. Stock Price, Fair Value and News

2.61USD-0.27 (-9.38%)Market Closed

Market Summary

HOWL
USD2.61-0.27
Market Closed
-9.38%

HOWL Stock Price

View Fullscreen

HOWL RSI Chart

HOWL Valuation

Market Cap

113.9M

Price/Earnings (Trailing)

-2.74

Price/Sales (Trailing)

5.7

Price/Free Cashflow

-2.94

HOWL Price/Sales (Trailing)

HOWL Profitability

Return on Equity

-35.36%

Return on Assets

-23.41%

Free Cashflow Yield

-34.01%

HOWL Fundamentals

HOWL Revenue

Revenue (TTM)

20.0M

Rev. Growth (Yr)

-79.64%

Rev. Growth (Qtr)

-74.85%

HOWL Earnings

Earnings (TTM)

-41.6M

Earnings Growth (Yr)

-35.14%

Earnings Growth (Qtr)

-34.91%

Breaking Down HOWL Revenue

Last 7 days

-16.3%

Last 30 days

-46.3%

Last 90 days

-56.6%

Trailing 12 Months

-7.1%

How does HOWL drawdown profile look like?

HOWL Financial Health

Current Ratio

6.71

HOWL Investor Care

Shares Dilution (1Y)

22.03%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202320.9M24.8M25.8M20.0M
20224.2M8.3M12.3M16.4M
202177.3K91.5K105.8K120.0K
202000063.0K

Tracking the Latest Insider Buys and Sells of Werewolf Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 06, 2023
ra capital management, l.p.
bought
4,095,130
2.21
1,853,000
-
Jan 12, 2022
seidel-dugan cynthia
acquired
111,838
2.81488
39,731
chief scientific officer
Dec 30, 2021
leonard reid
acquired
21,999
1.56
14,102
chief operating officer
Dec 15, 2021
leonard reid
sold
-40,241
13.4139
-3,000
chief operating officer
Jun 16, 2021
ra capital management, l.p.
bought
124,140
13.37
9,285
-
Jun 15, 2021
ra capital management, l.p.
bought
103,056
12.95
7,958
-
Jun 14, 2021
ra capital management, l.p.
bought
3,902,200
12.75
306,055
-
May 04, 2021
longwood fund iii gp, llc
bought
4,000,000
16.00
250,000
-
May 04, 2021
mpm bioventures 2014, l.p.
acquired
-
-
3,062,240
-
May 04, 2021
lazarus alon
acquired
-
-
1,646,640
-

1–10 of 31

Which funds bought or sold HOWL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-79,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
added
985
962,904
1,018,820
-%
May 15, 2024
MARSHALL WACE, LLP
new
-
170,320
170,320
-%
May 15, 2024
Brevan Howard Capital Management LP
new
-
122,537
122,537
-%
May 15, 2024
RA CAPITAL MANAGEMENT, L.P.
unchanged
-
16,099,600
39,818,800
0.51%
May 15, 2024
Laurion Capital Management LP
added
154
998,247
1,304,010
0.01%
May 15, 2024
Alyeska Investment Group, L.P.
reduced
-45.9
-154,453
1,527,370
0.01%
May 15, 2024
TWO SIGMA ADVISERS, LP
added
39.65
920,070
1,604,450
-%
May 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
unchanged
-
1,642,240
4,061,730
0.57%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
68,280
68,280
-%

1–10 of 48

Are Funds Buying or Selling HOWL?

Are funds buying HOWL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HOWL
No. of Funds

Unveiling Werewolf Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 07, 2024
ra capital management, l.p.
14.2%
6,192,881
SC 13D/A
Feb 14, 2024
ra capital management, l.p.
15.2%
6,179,035
SC 13D/A
Feb 14, 2024
pfm health sciences, lp
9.6%
6
SC 13G/A
Feb 13, 2024
bank of america corp /de/
5.8%
2,096,081
SC 13G
Feb 12, 2024
rubric capital management lp
5.35%
1,935,357
SC 13G/A
Dec 21, 2023
adage capital partners gp, l.l.c.
8.38%
3,034,255
SC 13G
Feb 10, 2023
rubric capital management lp
5.97%
1,835,387
SC 13G
Jan 17, 2023
pfm health sciences, lp
4.2%
6
SC 13G/A
Jan 17, 2023
pfm health sciences, lp
5.3%
6
SC 13G
Jan 10, 2023
ra capital management, l.p.
17.96%
6,159,054
SC 13D/A

Recent SEC filings of Werewolf Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 03, 2024
8-K
Current Report
May 28, 2024
8-K
Current Report
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading

Peers (Alternatives to Werewolf Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.91
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.69
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

Werewolf Therapeutics, Inc. News

Latest updates
StockTitan17 minutes ago

Werewolf Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue-100.0%-1,4835,8978,0814,5007,2834,9704,1482,08215.0037.0051.0017.0019.0022.0024.0067.00
Operating Expenses23.8%17,90414,46315,14814,14816,68720,46217,50919,12015,36617,88413,79510,9567,4527,3926,0535,0653,894
  S&GA Expenses3.8%4,9964,8144,3104,5654,9814,6034,4395,2334,4214,4844,0083,6912,6352,1061,2411,2851,131
  R&D Expenses33.8%12,9089,64910,8389,58311,70615,85913,07013,88710,94513,4009,7877,2654,8175,2864,8123,7802,763
Interest Expenses-32.8%1,0031,493904570172------------
Net Income-34.9%-16,193-12,003-8,285-5,098-11,982-11,930-11,943-14,594-15,343-17,869-13,758-10,921-7,435-7,402-6,0682,257-3,827
Net Income Margin-11.3%-2.08*-1.87*-1.45*-1.65*-2.41*-3.28*-4.85*-7.45*-13.82*-416.52*-373.67*-347.83*-241.40*-238.73*---
Free Cashflow-222.1%-15,408-4,783-7,429-11,103-10,066-12,388-16,426-1,414-13,979-12,945-12,519-10,571-7,339-6,018---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets1.6%17817517618519516017217516517917819089.0096.00
  Current Assets2.8%14213813914715714015215414516117418685.0093.00
    Cash Equivalents3.6%13913413013714813114014614415917218585.0093.00
  Net PPE-5.4%8.008.008.008.009.009.009.009.006.003.001.001.001.001.00
Liabilities-5.4%60.0063.0064.0067.0074.0038.0041.0045.0025.0026.009.009.007.007.00
  Current Liabilities9.5%21.0019.0014.0015.0022.0024.0028.0030.0011.0012.008.007.005.005.00
Shareholder's Equity5.6%118111112119121122131130139153169182--
  Retained Earnings-4.7%-360-344-332-323-318-306-294-282-268-252-235-221-153-51.86
  Additional Paid-In Capital4.9%478455445442440429426413408406404403--
Shares Outstanding10.7%43.0039.0036.0036.0035.0031.0030.0027.0027.0027.0027.0018.001.00-
Float----67.00---59.00---202--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-233.6%-15,297-4,585-7,208-10,921-9,898-11,870-14,472-303-13,951-12,673-12,417-10,460-7,326-6,009-4,921-4,295-3,399
  Share Based Compensation23.1%2,3051,8732,0971,9302,1081,9421,9361,7771,7451,2961,47978153922113322157.00
Cashflow From Investing43.9%-111-198-221-182-168-518-1,954-1,111-28.00-272-102-111-13.00-9.00-57.00-45.00-449
Cashflow From Financing123.3%20,2599,07341.0069248,6231,25611,0763,41515938.00-276110,203-53871,880-97.0022,074-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

HOWL Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Collaboration revenue$ 742$ 4,464
Operating expenses:  
Research and development12,90811,706
General and administrative4,9964,981
Total operating expenses17,90416,687
Operating loss(17,162)(12,223)
Other income:  
Interest income1,9731,519
Interest expense(1,003)(172)
Other expense, net(1)(1,106)
Total other income969241
Net loss$ (16,193)$ (11,982)
Net loss per share attributable to common stockholders, basic and diluted  
Net loss per common share, basic (in usd per share)$ (0.39)$ (0.34)
Net loss per common share, diluted (in usd per share)$ (0.39)$ (0.34)
Weighted-average common shares outstanding, basic and diluted  
Weighted-average common shares outstanding, basic (in shares)41,607,27934,784,682
Weighted -average common shares outstanding, diluted (in shares)41,607,27934,784,682

HOWL Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 139,189$ 134,343
Prepaid expenses and other current assets2,3202,677
Other receivables7751,350
Total current assets142,284138,370
Property and equipment, net7,5297,958
Restricted cash and cash equivalents, net of current portion21,02721,023
Operating lease right of use asset6,5126,888
Other assets248594
Total assets177,600174,833
Current liabilities:  
Accounts payable1,5941,336
Accrued expenses and other current liabilities6,2158,860
Operating lease liability, current1,2361,608
Deferred revenue, current502907
Note payable, current11,6676,667
Total current liabilities21,21419,378
Operating lease liability, net of current portion10,62010,992
Deferred revenue, net of current portion431433
Note payable, net of discount, issuance costs, and current portion27,74832,656
Total liabilities60,01363,459
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value, 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 43,282,371 and 39,107,048 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively44
Additional paid-in capital477,849455,443
Accumulated deficit(360,266)(344,073)
Total stockholders’ equity117,587111,374
Total liabilities and stockholders’ equity$ 177,600$ 174,833
HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://werewolftx.com
 INDUSTRYBiotechnology
 EMPLOYEES48

Werewolf Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Werewolf Therapeutics, Inc.? What does HOWL stand for in stocks?

HOWL is the stock ticker symbol of Werewolf Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Werewolf Therapeutics, Inc. (HOWL)?

As of Mon Jun 24 2024, market cap of Werewolf Therapeutics, Inc. is 113.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOWL stock?

You can check HOWL's fair value in chart for subscribers.

What is the fair value of HOWL stock?

You can check HOWL's fair value in chart for subscribers. The fair value of Werewolf Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Werewolf Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOWL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Werewolf Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether HOWL is over valued or under valued. Whether Werewolf Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Werewolf Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOWL.

What is Werewolf Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, HOWL's PE ratio (Price to Earnings) is -2.74 and Price to Sales (PS) ratio is 5.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOWL PE ratio will change depending on the future growth rate expectations of investors.